Skip to Main Content

Bellus Health, a small Canadian drug maker, is seeking to develop a potential blockbuster medicine for chronic cough that could surpass a competing drug from Merck.

Now, it’s nearing the completion of a mid-stage clinical trial that will serve as a pivotal test of whether it can pull that off.


Here are five things to know about the Bellus drug, its Phase 2 study, and expectations heading into the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!